Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.7.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents [note 4] $ 13,916 $ 15,233
Short-term investments [note 4]   10,230
Interest receivable   32
Amounts receivable 241 478
Prepaid expenses 307 954
Total current assets 14,464 26,927
Restricted cash [note 4 and note 7] 272 272
Property and equipment, net 129 258
Other assets 13 13
Total assets 14,878 27,470
Current liabilities:    
Accounts payable 233 2,121
Accrued liabilities other 1,056 2,442
Accrued clinical liabilities 50 3,415
Accrued compensation 254 188
Current portion of long-term obligations [note 7] 46 57
Warrant liability [note 4 and note 5 [f]] 114 232
Total current liabilities 1,753 8,455
Long-term obligations, less current portion [note 7] 22 49
Total liabilities 1,775 8,504
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 75,000,000 shares authorized, 30,138,488 and 30,059,514 issued at June 30, 2017 and December 31, 2016, respectively, and 30,104,495 and 30,025,521 outstanding at June 30, 2017 and December 31, 2016, respectively 30 29
Additional paid-in capital 213,662 213,239
Accumulated deficit (203,230) (196,942)
Accumulated other comprehensive income 2,641 2,640
Total stockholders' equity 13,103 18,966
Total liabilities and stockholders' equity $ 14,878 $ 27,470